Tagged with china

China In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem.   The 5000 square metre project, Roche’s first such in-house accelerator globally, builds on the company’s sizeable existing R&D presence in…

China The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.   How Hong Kong can cement its position as a biotech listing hub (SCMP) https://www.scmp.com/comment/opinion/article/3134767/how-hong-kong-can-cement-its-position-biotech-listing-hub To maintain its growth and…

Asia-Pacific Generics penetration in the Asia-Pacific region by country for 2018. A full 90.3 percent of all medicines dispensed in India were generics compared to 78.3 percent in China and 76.9 percent in Indonesia. At the other end of the scale, Japan and Taiwan had a generics penetration of just 28.9…

Asia-Pacific Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year and with deaths caused by cancer expected to increase by 36 percent by 2030, has a pressing need for more patient-centric, data-driven, value-based, and precise solutions in oncology. Additionally, Asian cancer patients’ healthcare needs can differ…

China Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player in the bispecific antibody field.   The Series C financing round means that the company has raised over USD 220…

China Genetron Health is a publicly-traded China-based precision oncology company, covering the “full-cycle” of cancer care, from early screening, diagnosis, and treatment recommendations to continuous monitoring care. CEO and Co-Founder Sizhen Wang explains how the company obtained US FDA Breakthrough Device Designation, analyzes the Chinese biotech sector, and highlights their objective…

China The latest China pharma news, including the upcoming first domestic approval for a foreign COVID-19 vaccine in June; the potential of Western China as a manufacturing hub; and EpimAb’s plan for a public stock offering in 2022 amid a booming global bispecific antibodies market.   Pharma Not Immune From Coming…

China In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai International Medical Center (SIMC) jointly established a Rehabilitation Medicine Center for stroke patients with the mission to bring and deliver German stroke rehabilitation treatment standards to patients in China.   According to Consanas Rehabilitation, there are…

China Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world, his talent strategy, and the use of AI within the sector.   BioDuro has very strong capabilities on the discovery…

China The Top 10 Chinese pharma companies for 2020 ranked by overall revenues. Taken from Fortune magazine’s 2020 list of the 500 biggest companies in China, this up-to-date list shows Shanghai Pharma in pole position, followed by China Resources Pharmaceutical, and Guangzhou Baiyunshan.     Made with Visme Infographic Maker

China Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into rare disease public insurance coverage across key cities in China.   On May 30, 2020, the China Organization for Rare Disorders (CORD) and the management consulting team…

China The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences.   AstraZeneca signs deal with Chinese biotech Junshi Biosciences to market anti-PD-1 cancer drug in China https://www.biopharma-reporter.com/Article/2021/03/01/AstraZeneca-betting-on-China-s-PD-1-cancer-market AstraZeneca has signed a…